Smeets Farma SPRL
Smeets Farma reported total assets of 526,110 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Smeets Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +69 % Total assets +25 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Smeets Farma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −20,008 € | ||||
| Equity | 445,753 € | ||||
| Cash | 270,500 € | ||||
| EBITDA | −3,542 € | ||||
| Total assets | 526,110 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 08 Jul 2025
- Year ended 31 Dec 2023filed on 03 Jul 2024
- Year ended 31 Dec 2022filed on 27 Jun 2023
- Year ended 31 Dec 2021filed on 06 Jul 2022
Smeets Farma's financial analysis
- Solvency84.7%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Smeets Farma
Smeets Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0413.340.952
- VAT number
- BE0413340952
- Peppol
- Registered · 0208:0413340952 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 11 Aug 1973
- Registered office
- 2570 Duffel
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Smeets Farma (SPRL) has been based in Duffel since 1973, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 20,008 € and equity of 445,753 €; its revenue is not published. Its solvency stands at 84.7%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Smeets Farma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek de Groof Retail sale of pharmaceutical products Antwerp · balance sheet 523,866 €
- Rudophar Retail sale of pharmaceutical products Oostkamp · balance sheet 526,499 €
- Ghekiere Retail sale of pharmaceutical products Zemst · balance sheet 525,361 €
- CFA Pharma Retail sale of pharmaceutical products Ypres · balance sheet 525,286 €
- Pharmacie du ROI Vainqueur Retail sale of pharmaceutical products Etterbeek · balance sheet 527,195 €
- LSRP Retail sale of pharmaceutical products Braives · balance sheet 527,233 €
- Apoteek Breckpot Retail sale of pharmaceutical products Aalst · balance sheet 523,391 €
- Duran Zehra Retail sale of pharmaceutical products Ghent · balance sheet 531,335 €
Frequently asked questions about Smeets Farma
What is the revenue of Smeets Farma?
Smeets Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Smeets Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE0413340952 for Smeets Farma, if the company is VAT-registered. Its company number (CBE) is 0413.340.952.
Where is the registered office of Smeets Farma?
According to the CBE register, the registered office of Smeets Farma is in 2570 Duffel.
What is the equity of Smeets Farma?
At the close of the 2025 financial year, the equity of Smeets Farma amounts to 445,753 €, a solvency of 84.7% of total assets.
Who manages Smeets Farma?
The register lists 1 active mandates at Smeets Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Smeets Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →